Want to get a sneak peek at the most exciting oncology advancements? ?? #ESMO24 is just around the corner, and we've got a special report highlighting the must-see LBAs. Get exclusive insights into potential treatment paradigm shifts across various tumor types featuring Alex Spira, MD, PhD, FACP, FASCO of Virginia Cancer Specialists, P.C., Neal Shore of Carolina Urologic Research Center, Giuseppe Curigliano, Robert M. Jotte, M.D. Ph.D., and more experts from Dana-Farber Cancer Institute, The US Oncology Network, ESMO - European Society for Medical Oncology! Don't miss out! Click here to access the full report: https://lnkd.in/ekn6h5Z4
Targeted Oncology
在线音视频媒体
Cranbury Township，New Jersey 53,582 位关注者
The Community Resource in Targeted Therapies
关于我们
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- 网站
-
https://targetedonc.com
Targeted Oncology的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 2-10 人
- 总部
- Cranbury Township，New Jersey
- 类型
- 上市公司
- 领域
- Oncology、Healthcare Communications、Healthcare、Cancer Research、Targeted Therapies、Community Oncology、Cancer、Cancer Treatment和Oncologists
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury Township
Targeted Oncology员工
动态
-
A phase 3 trial has initiated to evaluate bomedemstat, an investigational agent for the treatment of patients with essential thrombocythemia who have previously not received cytoreductive therapy. #MPNSM | Merck https://lnkd.in/ewWGTuVh
-
BREAKING: The #FDA has approved the subcutaneous formulation of atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for all adult indications of the intravenous version of the agent. https://lnkd.in/eZ7c8H86
-
-
The latest episode of The Show and After Show shines a light on #ESMO24 and the critical data being presented. Access this exclusive preview here https://ow.ly/SERb50TmnaQ as we highlight upcoming studies that hold significant promise. Plus, hear our take on the growing role of AI in cancer care and helpful insights for those traveling to Barcelona. Don’t miss out.
-
-
The #FDA has cleared an investigational new drug application for VNX-101 for the treatment of CD19+ acute lymphoblastic leukemia. #LEUSM https://lnkd.in/eq42JZEg
FDA Clears IND of VNX-101 in CD19+ Acute Lymphoblastic Leukemia
targetedonc.com
-
The #FDA has granted orphan drug designation to elraglusib for the treatment of patients with soft tissue #sarcoma. https://lnkd.in/eAkiCr5C
FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma
targetedonc.com
-
HER2DX has shown its ability to predict patient outcomes, according to a recent study where the assay was used to evaluate tumor samples from 214 patients with advanced HER2+ disease. https://lnkd.in/eM3t4Kzu
HER2DX Offers Valuable Tool for Clinicians Treating HER2+ Breast Cancer
targetedonc.com
-
Mirvetuximab soravtansine demonstrated positive results for FRα+ ovarian cancer in the MIRASOL trial, improving PFS, ORR, and OS over chemotherapy. #ovariancancer #Elahere #MIRASOL | Royal Marsden Hospital https://lnkd.in/e-3kgApQ
Mirvetuximab Soravtansine Shows Efficacy in Ovarian Cancer Despite Dose Adjustments
targetedonc.com
-
Dato-DXd numerically improved OS vs docetaxel in patients with locally advanced or metastatic #NSCLC treated with at least 1 prior line of therapy, but the improvement was not statistically significant, according to data at #WCLC24. https://lnkd.in/eqya2Mhq
In TROPION-Lung01, Dato-DXd Continues to Show Promise in NSCLC
targetedonc.com
-
The #FDA has granted orphan drug designation to certepetide for the treatment of cholangiocarcinoma. https://lnkd.in/ejWXDvrY
Certepetide Wins FDA Orphan Drug Designation in Cholangiocarcinoma
targetedonc.com